Found: 76
Select item for more details and to access through your institution.
A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation.
- Published in:
- NPJ Precision Oncology, 2024, v. 8, n. 1, p. 1, doi. 10.1038/s41698-024-00698-4
- By:
- Publication type:
- Article
TICTOC: A Phase I/II Study of Tamoxifen and SUBA-Itraconazole Combination Testing in Platinum-Resistant Ovarian Cancer (PROC).
- Published in:
- Journal of Immunotherapy & Precision Oncology, 2024, v. 7, n. 3, p. 225, doi. 10.36401/JIPO-24-X2
- By:
- Publication type:
- Article
A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 2, p. 278, doi. 10.1007/s10637-017-0553-x
- By:
- Publication type:
- Article
ENZA‐p trial protocol: a randomized phase II trial using prostate‐specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration‐resistant prostate cancer treated with enzalutamide (ANZUP 1901)
- Published in:
- BJU International, 2021, v. 128, n. 5, p. 642, doi. 10.1111/bju.15491
- By:
- Publication type:
- Article
UpFrontPSMA: a randomized phase 2 study of sequential <sup>177</sup>Lu‐PSMA‐617 and docetaxel vs docetaxel in metastatic hormone‐naïve prostate cancer (clinical trial protocol).
- Published in:
- BJU International, 2021, v. 128, n. 3, p. 331, doi. 10.1111/bju.15384
- By:
- Publication type:
- Article
Understanding the role of new systemic agents in the treatment of prostate cancer.
- Published in:
- BJU International, 2016, v. 118, p. 8, doi. 10.1111/bju.13633
- By:
- Publication type:
- Article
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma.
- Published in:
- JAMA: Journal of the American Medical Association, 2014, v. 311, n. 23, p. 2397, doi. 10.1001/jama.2014.6096
- By:
- Publication type:
- Article
Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis.
- Published in:
- Genome Medicine, 2021, v. 13, n. 1, p. 1, doi. 10.1186/s13073-021-00885-z
- By:
- Publication type:
- Article
ADVANCES IN THE ADJUVANT TREATMENT OF COLORECTAL CANCER.
- Published in:
- ANZ Journal of Surgery, 2006, v. 76, n. 5, p. 373, doi. 10.1111/j.1445-2197.2006.03726.x
- By:
- Publication type:
- Article
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT).
- Published in:
- Therapeutic Advances in Medical Oncology, 2023, p. 1, doi. 10.1177/17588359231156392
- By:
- Publication type:
- Article
Increased treatment-related toxicity subsequent to an anti-PD-1 agent.
- Published in:
- Current Oncology, 2015, v. 22, n. 4, p. e320, doi. 10.3747/co.22.2418
- By:
- Publication type:
- Article
A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations.
- Published in:
- British Journal of Cancer, 2023, v. 129, n. 3, p. 475, doi. 10.1038/s41416-023-02311-0
- By:
- Publication type:
- Article
Conjunctival Melanoma in Childhood and Adolescence: A Systematic Review.
- Published in:
- Ocular Oncology & Pathology, 2019, v. 5, n. 6, p. 387, doi. 10.1159/000497813
- By:
- Publication type:
- Article
Expansion of Lymphocytes from Prostatic Adenocarcinoma and Adjacent Nonmalignant Tissue.
- Published in:
- Prostate Cancer (20903111), 2022, p. 1, doi. 10.1155/2022/6499344
- By:
- Publication type:
- Article
Chemotherapy in Cutaneous Melanoma: Is There Still a Role?
- Published in:
- Current Oncology Reports, 2023, v. 25, n. 6, p. 609, doi. 10.1007/s11912-023-01385-6
- By:
- Publication type:
- Article
Utility of <sup>64</sup>Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on <sup>68</sup>Ga-PSMA-11 PET/CT.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 8, p. 1, doi. 10.2967/jnumed.124.267881
- By:
- Publication type:
- Article
<sup>177</sup>Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing <sup>177</sup>Lu-PSMA-I&T Therapy.
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 3, p. 410, doi. 10.2967/jnumed.122.264677
- By:
- Publication type:
- Article
Evaluation of <sup>177</sup>Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective <sup>177</sup>Lu-PSMA-617 and NOX66 Combination Trial (LuPIN).
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 2, p. 221, doi. 10.2967/jnumed.122.264398
- By:
- Publication type:
- Article
The Prognostic Value of Posttreatment <sup>68</sup>Ga-PSMA-11 PET/CT and <sup>18</sup>F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with <sup>177</sup>Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN).
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 1, p. 69, doi. 10.2967/jnumed.122.264104
- By:
- Publication type:
- Article
<sup>177</sup>Lu-PSMA SPECT Quantitation at 6 Weeks (dose 2) Predicts Short Progression Free Survival for Patients Undergoing Lu PSMA I&T Therapy.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.122.264677
- By:
- Publication type:
- Article
Evaluation of <sup>177</sup>Lu-PSMA SPECT Quantitation as a Response Biomarker within a Prospective <sup>177</sup>Lu-PSMA-617 and NOX66 Combination Trial (LuPIN).
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.122.264398
- By:
- Publication type:
- Article
The prognostic value of post-treatment PSMA and FDG PET/CT in metastatic, castration-resistant prostate cancer treated with 177LuPSMA-617 and NOX66 in a phase I/II trial (LuPIN).
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.122.264104
- By:
- Publication type:
- Article
<sup>177</sup> Lu-PSMA SPECT Quantitation at 6 Weeks (dose 2) Predicts Short Progression Free Survival for Patients Undergoing Lu PSMA I&T Therapy.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 1, doi. 10.2967/jnumed.122.264677
- By:
- Publication type:
- Article
Evaluation of <sup>177</sup>Lu-PSMA SPECT Quantitation as a Response Biomarker within a Prospective <sup>177</sup>Lu-PSMA-617 and NOX66 Combination Trial (LuPIN).
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 1, doi. 10.2967/jnumed.122.264398
- By:
- Publication type:
- Article
The prognostic value of post-treatment PSMA and FDG PET/CT in metastatic, castration-resistant prostate cancer treated with 177LuPSMA-617 and NOX66 in a phase I/II trial (LuPIN).
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 1, doi. 10.2967/jnumed.122.264104
- By:
- Publication type:
- Article
The prognostic value of post-treatment PSMA and FDG PET/CT in metastatic, castration-resistant prostate cancer treated with 177LuPSMA-617 and NOX66 in a phase I/II trial (LuPIN).
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 7, p. 1, doi. 10.2967/jnumed.122.264104
- By:
- Publication type:
- Article
<sup>177</sup>Lutetium-PSMA-617 and idronoxil (NOX66) in men with end-stage metastatic castration-resistant prostate cancer (LuPIN): Patient outcomes and predictors of treatment response of a Phase I/II trial.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.121.262552
- By:
- Publication type:
- Article
<sup>177</sup>Lutetium-PSMA-617 and idronoxil (NOX66) in men with end-stage metastatic castration-resistant prostate cancer (LuPIN): Patient outcomes and predictors of treatment response of a Phase I/II trial.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.121.262552
- By:
- Publication type:
- Article
<sup>177</sup>Lutetium-PSMA-617 and idronoxil (NOX66) in men with end-stage metastatic castration-resistant prostate cancer (LuPIN): Patient outcomes and predictors of treatment response of a Phase I/II trial.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.121.262552
- By:
- Publication type:
- Article
<sup>177</sup>Lutetium-PSMA-617 and idronoxil (NOX66) in men with end-stage metastatic castration-resistant prostate cancer (LuPIN): Patient outcomes and predictors of treatment response of a Phase I/II trial.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.121.262552
- By:
- Publication type:
- Article
Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial <sup>68</sup>Ga-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen Blockade.
- Published in:
- Journal of Nuclear Medicine, 2019, v. 60, n. 7, p. 950, doi. 10.2967/jnumed.118.223099
- By:
- Publication type:
- Article
Treatment Outcomes from 68Ga-PSMA PET/CT-Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET.
- Published in:
- Journal of Nuclear Medicine, 2017, v. 58, n. 12, p. 1972, doi. 10.2967/jnumed.117.196683
- By:
- Publication type:
- Article
Extracellular vesicles from biological fluids as potential markers in castration resistant prostate cancer.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 8, p. 4701, doi. 10.1007/s00432-022-04391-6
- By:
- Publication type:
- Article
Oncology in 2050 – A Retrospective?
- Published in:
- Oncologist, 2020, v. 25, n. 7, p. e1127, doi. 10.1634/theoncologist.2019-0887
- By:
- Publication type:
- Article
Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration‐Resistant Prostate Cancer (mCRPC).
- Published in:
- Oncologist, 2019, v. 24, n. 9, p. 1188, doi. 10.1634/theoncologist.2018-0621
- By:
- Publication type:
- Article
Cancer patients' experiences with immune checkpoint modulators: A qualitative study.
- Published in:
- Cancer Medicine, 2020, v. 9, n. 9, p. 3015, doi. 10.1002/cam4.2940
- By:
- Publication type:
- Article
The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma.
- Published in:
- Cancer Medicine, 2016, v. 5, n. 10, p. 2792, doi. 10.1002/cam4.878
- By:
- Publication type:
- Article
Expansion and Characterization of Human Melanoma Tumor-Infiltrating Lymphocytes (TILs).
- Published in:
- PLoS ONE, 2010, v. 5, n. 11, p. 1, doi. 10.1371/journal.pone.0013940
- By:
- Publication type:
- Article
Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgen‐receptor–targeted therapy for metastatic castration‐resistant prostate cancer.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 14, p. 2587, doi. 10.1002/cncr.33523
- By:
- Publication type:
- Article
To ban or not to ban tanning bed use for minors: A cost‐effectiveness analysis from multiple US perspectives for invasive melanoma.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 13, p. 2333, doi. 10.1002/cncr.33499
- By:
- Publication type:
- Article
Hyperprogressive disease in early‐phase immunotherapy trials: Clinical predictors and association with immune‐related toxicities.
- Published in:
- Cancer (0008543X), 2019, v. 125, n. 8, p. 1341, doi. 10.1002/cncr.31999
- By:
- Publication type:
- Article
Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma.
- Published in:
- 2009
- By:
- Publication type:
- journal article
Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers.
- Published in:
- BJU International, 2012, v. 110, n. 6, p. 840, doi. 10.1111/j.1464-410X.2011.10922.x
- By:
- Publication type:
- Article
The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors.
- Published in:
- Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-34012-2
- By:
- Publication type:
- Article
Renal cell carcinoma bone metastases: clinical advances.
- Published in:
- Therapeutic Advances in Medical Oncology, 2010, v. 2, n. 2, p. 75, doi. 10.1177/1758834009358417
- By:
- Publication type:
- Article
Oncogenic signaling in uveal melanoma.
- Published in:
- Pigment Cell & Melanoma Research, 2018, v. 31, n. 6, p. 661, doi. 10.1111/pcmr.12708
- By:
- Publication type:
- Article